Pharma boards don’t just oversee pipelines anymore—they oversee patent risk as a governance problem.
That’s the shift behind the latest conversation in IP strategy: translating litigation outcomes, expiry timelines, and infringement exposure into metri…

Designing Around Formulation Patents: The Generic Developer’s Playbook (and Why It’s Getting Harder)
In generic drug development, the bottleneck isn’t always the API. It’s the formulation—and the patents that quietly sit between “we can make it” and “w…

Pharma forensics is having a moment—and it’s not because the science got easier.
It’s because the playbook got harder to hide.
In drug development, the “lifecycle strategy” conversation usually stays high-level: new indications, new dosages, new geogra…

Designing Around the Moat: How Generic Developers Can Navigate Secondary Formulation Patents
In generic drug development, the real fight often isn’t over the original patent—it’s over what comes after.
The first patent in a portfolio is the headline. B…

The “Patent Cliff” Isn’t a Cliff—It’s a Supply-Chain Forecasting Problem.
If you work in pharma supply chain, procurement, planning, or commercial operations, you’ve probably heard the phrase “patent cliff” used like a weather forecast: sudden, unavoid…

AI is getting better at finding what patent examiners miss—because it’s learning to read between the lines.
For years, “prior art search” has been treated like a keyword game: throw the right terms into the right database, filter the noise, and hope th…

Your competitor doesn’t need to “beat” your patent to win. They just need to design around it.
In pharma, the most expensive battles aren’t always fought in court—they’re fought in the lab, in the filing strategy, and in the quiet decisions made long b…

Formulation forensics is the new competitive intelligence. Here’s how to read it in drug patent claims.
Drug development is often described as a race for molecules. But in the real world, the race increasingly turns on something less glamorous—and far …

The Biosimilar Patent Dance Is Not a Game—It’s a Strategy Test. Here’s How to Win.
If you’re a biologics innovator or a biosimilar applicant, you already know the “patent dance” isn’t about choreography. It’s about leverage—timing, information, and the…

Generic manufacturers don’t “wait” for exclusivity—they engineer it.
In the pharmaceutical market, the first 180 days after a Paragraph IV win aren’t just a legal milestone. They’re a competitive weapon. And the companies that consistently capture th…